BOULDER, Colorado | December 24, 2025 — Edgewise Therapeutics announced the completion of Parts B and C of the CIRRUS-HCM Phase 2 clinical trial evaluating EDG-7500, alongside favorable interim safety results from the ongoing Part D study in patients with Hypertrophic cardiomyopathy (HCM). The update confirms that EDG-7500 was generally well tolerated, with no clinically meaningful reductions in left ventricular ejection fraction (LVEF) and no LVEF values falling below 50%, supporting continued development toward Phase 3.
Science Significance
Scientifically, the data reinforce EDG-7500’s novel mechanism as a selective cardiac sarcomere modulator designed to slow early contraction velocity while preserving systolic function, a critical balance in HCM management. Across Parts B and C, EDG-7500 demonstrated improvements in multiple disease-relevant biomarkers and functional endpoints, including NT-proBNP, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, NYHA functional class, and left ventricular outflow tract gradient in obstructive HCM. Importantly, interim Part D results showed no exposure-dependent correlation between plasma concentration and LVEF decline, differentiating EDG-7500 from other cardiac myosin inhibitors and strengthening its best-in-disease scientific profile.
Regulatory Significance
From a regulatory perspective, the completion of Phase 2 Parts B and C and the ongoing execution of Part D reflect robust compliance with ICH-GCP standards, including structured safety monitoring and protocol-driven dose optimization. Part D is specifically designed to inform exposure-response relationships and biomarker-guided dosing, data sets that are highly relevant for regulatory discussions and Phase 3 trial design. The absence of clinically significant systolic dysfunction and the favorable arrhythmia profile observed to date reduce regulatory risk and support advancement into late-stage development under heightened regulatory scrutiny.
Business Significance
Advertisement
Strategically, the update represents a value-inflection milestone for Edgewise Therapeutics. Completion of multiple Phase 2 components de-risks the EDG-7500 program and provides clear visibility toward a planned Phase 3 initiation in the fourth quarter of 2026. Demonstrating a differentiated safety profile relative to existing therapies strengthens EDG-7500’s commercial positioning in a competitive cardiovascular market. The company’s ability to exceed enrollment targets and maintain trial momentum also signals operational strength and disciplined clinical execution, key factors for investors and strategic partners.
Patients’ Significance
For patients, the results are particularly meaningful. Hypertrophic cardiomyopathy affects approximately one in 500 people worldwide and is associated with significant symptom burden, reduced quality of life, and increased risk of heart failure and sudden cardiac death. Many current therapies require intensive monitoring due to concerns over systolic dysfunction. EDG-7500’s preservation of LVEF and favorable tolerability profile suggests the potential for broader use across obstructive and nonobstructive HCM populations, potentially expanding access beyond specialized centers and reducing monitoring burdens for patients and clinicians.
Policy Significance
At a policy level, the trial progress highlights the importance of innovative cardiovascular drug development aligned with patient safety and real-world feasibility. Therapies that maintain cardiac function while improving diastolic performance align with healthcare system goals to reduce hospitalization, improve long-term outcomes, and manage chronic genetic diseases more effectively. The extensive use of continuous cardiac monitoring and biomarker-guided dosing in CIRRUS-HCM also reflects evolving expectations for data-driven, patient-centric clinical trial design encouraged by regulators and policymakers.
Overall, the CIRRUS-HCM Phase 2 update positions EDG-7500 as a clinically differentiated and regulatorily credible candidate in the treatment of hypertrophic cardiomyopathy. With completed Phase 2 cohorts, encouraging interim safety data, and a clear path toward Phase 3, Edgewise Therapeutics continues to advance a therapy that may redefine the balance between efficacy and safety in HCM management. For the clinical and regulatory community, the results underscore how rigorous trial execution and safety-focused innovation can accelerate progress toward meaningful patient benefit.
Source: Edgewise Therapeutics press release
